Search
Displaying 221–230 of 585 for “Retinitis pigmentosa”
-
Beacon Stories
Lindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Invisible Disability
When I walk around the neighborhood with my white cane, I still worry about stigma and how people perceive me. I’ve had to remind myself that the cane is a tool to keep me safe.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Eye on the Cure Podcast | Episode 88: Richard Small
Eye on the CureRichard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Research NewsDr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
